Evidence map›Paper›PMID 39273438›Full record

ArticleInternational journal of molecular sciences2024

An Inducible Luminescent System to Explore Parkinson's Disease-Associated Genes.

Anelya Gandy, Gilles Maussion, Sara Al-Habyan, Michael Nicouleau, Zhipeng You, Carol X-Q Chen, Narges Abdian, Nathalia Aprahamian, Andrea I Krahn, Louise Larocque and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anelya GandyThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.
Gilles MaussionThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.ORCID 0000-0001-5785-6238
Sara Al-HabyanCentre for Oncology, Radiopharmaceuticals and Research (CORR), Biologic and Radiopharmaceutical Drugs Directorate (BRDD), Health Products and Food Branch (HPFB), Health Canada, Ottawa, ON K1A 0K9, Canada.
Michael NicouleauThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.
Zhipeng YouThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.
Carol X-Q ChenThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.
Narges AbdianThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.
Nathalia AprahamianThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.
Andrea I KrahnThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.ORCID 0000-0002-7975-6489
Louise LarocqueCentre for Oncology, Radiopharmaceuticals and Research (CORR), Biologic and Radiopharmaceutical Drugs Directorate (BRDD), Health Products and Food Branch (HPFB), Health Canada, Ottawa, ON K1A 0K9, Canada.
Thomas M DurcanThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.ORCID 0000-0003-3942-1956
Eric DeneaultCentre for Oncology, Radiopharmaceuticals and Research (CORR), Biologic and Radiopharmaceutical Drugs Directorate (BRDD), Health Products and Food Branch (HPFB), Health Canada, Ottawa, ON K1A 0K9, Canada.ORCID 0000-0002-6875-0380

Funding

Michael J. Fox Foundation for Parkinson's disease MJFF-020717
6 · The paper itself

Abstract

With emerging genetic association studies, new genes and pathways are revealed as causative factors in the development of Parkinson's disease (PD). However, many of these PD genes are poorly characterized in terms of their function, subcellular localization, and interaction with other components in cellular pathways. This represents a major obstacle towards a better understanding of the molecular causes of PD, with deeper molecular studies often hindered by a lack of high-quality, validated antibodies for detecting the corresponding proteins of interest. In this study, we leveraged the nanoluciferase-derived LgBiT-HiBiT system by generating a cohort of tagged PD genes in both induced pluripotent stem cells (iPSCs) and iPSC-derived neuronal cells. To promote luminescence signals within cells, a master iPSC line was generated, in which LgBiT expression is under the control of a doxycycline-inducible promoter. LgBiT could bind to HiBiT when present either alone or when tagged onto different PD-associated proteins encoded by the genes

Indexed as

Induced Pluripotent Stem CellsParkinson Diseasealpha-SynucleinGlucosylceramidaseHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2NeuronsProtein KinasesPTEN-Induced Putative KinaseUbiquitin-Protein LigasesVesicular Transport Proteinsalpha-SynucleinGBA protein, humanGlucosylceramidaseLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanparkin proteinProtein KinasesPTEN-Induced Putative KinaseSNCA protein, humanUbiquitin-Protein LigasesVesicular Transport ProteinsVPS35 protein, humancell-based assaysGBA1HiBiT-LgBiT technologyiPSC-derived modelsParkinson’s disease

Identifiers

PMID39273438
PMCPMC11395715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.